These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 8315378)

  • 1. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity elicited by rBCG vaccines.
    Stover CK; Bansal GP; Langerman S; Hanson MS
    Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
    Langermann S; Palaszynski S; Sadziene A; Stover CK; Koenig S
    Nature; 1994 Dec; 372(6506):552-5. PubMed ID: 7990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
    Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
    Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
    Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
    Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
    Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
    Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
    Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.
    Probert WS; LeFebvre RB
    Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.
    Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R
    Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
    Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
    Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination as a modality to prevent Lyme disease. A status report.
    Wormser GP
    Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.